Together our findings support the clinical relevance of PHGDH as a therapeutic target in medulloblastoma, with higher expression observed in MYC-amplified MBGRP3 defining a patient population that would most benefit from PHGDH perturbation. Here, MYC is linked to medulloblastoma.